• Christopher Symonds, Gregory Kline, Inelda Gjata, Marianne Sarah Rose, Maggie Guo, Lara Cooke, and Christopher Naugler.
• Department of Medicine/Endocrinology (Symonds, Kline), Physician Learning Program (Gjata), Department of Clinical Neurosciences (Cooke) and Department of Pathology and Laboratory Medicine (Naugler), Cummin... more g School of Medicine, University of Calgary; Health Services Statistical & Analytic Methods (Rose) and Alberta Precision Laboratories (Guo), Alberta Health Services, Calgary, Alta. less
• CMAJ. 2020 May 4; 192 (18): E469-E475.

BackgroundPrescribing of levothyroxine and rates of thyroid function testing may be sensitive to minor changes in the upper limit of the reference range for thyroid-stimulating hormone (TSH) that increase the proportion of abnormal results. We evaluated the population-level change in levothyroxine prescribing and TSH testing after a minor planned decrease in the upper limit of the reference range for TSH in a large urban centre with a single medical laboratory.MethodsUsing provincial administrative data, we compared predicted volumes of TSH tests with actual TSH test volumes before and after a planned change in the TSH reference range. We also determined the number of new levothyroxine prescriptions for previously untreated patients and the rate of changes to the prescribed dose for those on previously stable, long-term levothyroxine therapy before and after the change in the TSH reference range.ResultsBefore the change in the TSH reference range, actual and predicted monthly volumes of TSH testing followed an identical course. After the change, actual test volumes exceeded predicted test volumes by 7.3% (95% confidence interval [CI] 5.3%-9.3%) or about 3000 to 5000 extra tests per month. The proportion of patients with newly "abnormal" TSH results almost tripled, from 3.3% (95% CI 3.2%-3.4%) to 9.1% (95% CI 9.0%-9.2%). The rate of new levothyroxine prescriptions increased from 3.24 (95% CI 3.15-3.33) per 1000 population in 2013 to 4.06 (95% CI 3.96-4.15) per 1000 population in 2014. Among patients with preexisting stable levothyroxine therapy, there was a significant increase in the number of dose escalations (p < 0.001) and a total increase of 500 new prescriptions per month.InterpretationOur findings suggest that clinicians may have responded to mildly elevated TSH results with new or increased levothyroxine prescriptions and more TSH testing. Knowledge translation efforts may be useful to accompany minor changes in reference ranges.© 2020 Joule Inc. or its licensors.

14 keywords...

hide…